Cerebrospinal fluid orexin in Alzheimer's disease: a systematic review and meta-analysis.
Cerebrospinal fluid orexin in Alzheimer's disease: a systematic review and meta-analysis.
复制标题
脑脊液增食欲素治疗阿尔茨海默病：一项系统回顾和荟萃分析。
DOI：
10.1016/j.sleep.2021.07.007
复制
发表时间：
2021-09
期刊：
影响因子：
4.8
通讯作者：
Plante DT
中科院分区：
文献类型：
--
作者：
Treu SP;Plante DT
越来越多的证据表明，睡眠和阿尔茨海默病(AD)之间存在双向关系。新出现的研究还表明，参与睡眠-觉醒调节的关键神经递质食欲素在阿尔茨海默病患者中可能会发生变化，然而，先前的研究结果并不一致。这项调查既是为了评估汇总的文献，以最大限度地减少偏见的风险，也是为了确定与研究中的异质性相关的潜在因素。系统回顾确定了比较AD患者和对照组脑脊液增食欲素的相关研究。Meta分析(随机效应模型)比较AD和对照组中食欲素的效应大小(Hedge‘s g)。此外，还对感兴趣的关键变量进行了Meta回归，以评估研究之间异质性的潜在原因。确定了17项符合纳入/排除标准的研究。没有发现发表偏见的证据。与对照组相比，AD组的增食欲素水平没有显著升高，研究之间存在中等到很大的异质性(Hedge‘s g=0.2，p=0.136，I2=72.6%)。Meta回归分析显示，与对照组相比，出版年限(β=0.055，p=0.020)和磷酸化tau的效应大小(β=0.417，p=0.031)与增食欲素的差异有关。结果并不支持AD患者与对照组相比增食欲素的广泛差异，然而，不断发展的诊断标准可能已经影响了跨研究的结果。未来的研究将在阿尔茨海默病的纵向过程中检查食欲素，并探索磷酸化的tau和食欲素之间的潜在联系。
A growing body of evidence suggests that sleep and Alzheimer’s disease (AD) have a bi-directional relationship. Emerging research also suggests that orexin, a key neurotransmitter involved in sleep-wake regulation, may be altered in persons with AD, however results have not been consistent across prior studies. This investigation was conducted to both evaluate the aggregate literature to minimize the risk of bias and identify potential factors associated with heterogeneity across studies. Systematic review identified relevant investigations that compared cerebrospinal fluid orexin in persons with AD and controls. Meta-analysis (random effects model) compared effect size (Hedge’s g) for orexin between AD and controls. Meta-regression was additionally performed for key variables of interest to evaluate potential causes of heterogeneity among studies. 17 studies were identified that met inclusion/exclusion criteria. Evidence of publication bias was not identified. Non-significant increases in orexin were observed in AD relative to controls, with moderate to large heterogeneity among studies (Hedge’s g=0.20, p=0.136, I2=72.6%). Meta-regression demonstrated both year of publication (β=0.055, p=0.020) and effect size for phosphorylated tau in AD versus controls (β=0.417, p=0.031) were associated with differences in orexin. Results do not support broad differences in orexin in AD compared to controls, however, evolving diagnostic criteria may have affected findings across studies. Future research that examines orexin in AD over the longitudinal course of the disorder and explores potential links between phosphorylated tau and orexin are indicated.
登录
查看更多内容
DOI：
10.1126/science.1180962
发表时间：
2009-11-13
期刊：
Science (New York, N.Y.)
影响因子：
--
作者：
Kang JE;Lim MM;Bateman RJ;Lee JJ;Smyth LP;Cirrito JR;Fujiki N;Nishino S;Holtzman DM
通讯作者：
Holtzman DM
影响因子：
5.2
作者：
Inutsuka A;Yamanaka A
通讯作者：
Yamanaka A
影响因子：
1.9
作者：
Duval, S;Tweedie, R
通讯作者：
Tweedie, R
影响因子：
4.8
作者：
Dauvilliers, Yves A.;Lehmann, Sylvain;Gabelle, Audrey
通讯作者：
Gabelle, Audrey
阿尔茨海默氏病和额颞痴呆症中的CSF亲蛋白和淀粉样蛋白-β38表达。
影响因子：
4.2
作者：
Heywood WE;Hallqvist J;Heslegrave AJ;Zetterberg H;Fenoglio C;Scarpini E;Rohrer JD;Galimberti D;Mills K
通讯作者：
Mills K